Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
Recruiting in Palo Alto (17 mi)
+105 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Boehringer Ingelheim
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension (SBP\>=160 mmHg and Diastolic Blood Pressure(DBP)\>=100 mmHg).
Research Team
BI
Boehringer Ingelheim
Principal Investigator
Boehringer Ingelheim
Eligibility Criteria
Inclusion Criteria
Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation;
Age 18 years or older;
Patients with grade 2 or grade 3 hypertension as defined SBP>=160 mmHg and DBP>=100 mmHg at randomization
See 1 more
Treatment Details
Interventions
- Telmisartan 80mg Plus Hydrochlorothiazide 25mg (Angiotensin II Receptor Blocker/Thiazide Diuretic Combination)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Telmisartan/hydrochlorothiazideExperimental Treatment2 Interventions
Telmisartan80mg/Hydrochlorothiazide25mg
Group II: TelmisartanActive Control1 Intervention
Telmisartan 80 mg
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
502.550.01008 Boehringer Ingelheim Investigational SiteAthens, AL
502.550.01006 Boehringer Ingelheim Investigational SiteSt. Louis, MO
502.550.01019 Boehringer Ingelheim Investigational SiteMobile, AL
502.550.01009 Boehringer Ingelheim Investigational SiteNew Orleans, LA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Boehringer Ingelheim
Lead Sponsor
Trials
2566
Patients Recruited
16,150,000+